Partnership Revenue was Orchestra BioMed Holdings’s largest product and service line in fiscal 2025, bringing in $32.87M of $33.48M (98%).
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Partnership Revenue | $2.86M | $2.11M | $2.01M | $32.87M |
| Product Revenue | $671.00K | $654.00K | $633.00K | $611.00K |
| Total | $3.53M | $2.76M | $2.64M | $33.48M |
Orchestra BioMed Holdings brought in $33.48M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 1,169.2% from $2.64M in fiscal 2024. Partnership Revenue was the largest at $32.87M (98.2%), ahead of Product Revenue at $611.00K (1.8%).
From fiscal 2022 to 2025, combined revenue from these lines grew from $3.53M to $33.48M, a compound annual growth rate of 111.6%. Partnership Revenue's share of the total rose from 81.0% to 98.2%.
Orchestra BioMed Holdings (OBIO) reports its revenue by product and service. In fiscal 2025, Partnership Revenue was its largest product and service line, bringing in $32.87M (98.2% of the total), followed by Product Revenue at $611.00K (1.8%).
Partnership Revenue was Orchestra BioMed Holdings' largest product and service line in fiscal 2025, bringing in $32.87M, or 98.2% of the $33.48M total across its two product and service lines.
Every figure comes from Orchestra BioMed Holdings' annual financial filings, as reported. Each line keeps the name Orchestra BioMed Holdings gives it, and years follow its fiscal calendar.
Orchestra BioMed Holdings' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.